Taro admits collusion to end DOJ probe
Taro Pharmaceuticals has entered into a deferred prosecution agreement with the Antitrust Division, but it is costing the generic drugmaker $419 million and an admission that its price-fixing conspiracy impacted more than $500 million worth of commerce.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10